Comparative Pharmacology
Head-to-head clinical analysis: ACTICORT versus METHYLPREDNISOLONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICORT versus METHYLPREDNISOLONE ACETATE.
ACTICORT vs METHYLPREDNISOLONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Methylprednisolone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene expression to suppress inflammation, immune response, and adrenal function. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and decreases cytokine production.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
40-80 mg intramuscular (IM) or intra-articular (IA) injection; for IM use, dose may be repeated every 1-4 weeks as needed. Maximum single IM dose: 120 mg.
None Documented
None Documented
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Terminal half-life: 3-3.5 hours; correlates with duration of anti-inflammatory effect due to receptor-mediated action.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Renal: <10% unchanged; extensive hepatic metabolism to inactive metabolites primarily excreted renally as glucuronides and sulfates.
Category C
Category D/X
Corticosteroid
Corticosteroid